Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dietary Protein Supplementation and Semaglutide for Weight Loss
NCT06989203Recruiting
- Sponsor
- Chinese Academy of Sciences
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of semaglutide in obesity (4 arms), sponsored by Chinese Academy of Sciences. Primary endpoint: Change in Body Weight at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06989203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989203.